한글목차

바이오매뉴팩처링 세계 시장 규모는 2024년에 190억 8,000만 달러로 평가되었고, 2030년까지의 예측 기간 동안 CAGR 7.72%로 성장할 전망입니다.

바이오매뉴팩처링 시장은 바이오테크놀러지 및 제약업계에서 중요한 부분이며, 생물학적 유래 제품의 대규모 생산에 초점을 맞추었습니다. 여기에는 단일클론항체, 치료용 단백질, 세포 및 유전자 치료제, 백신 및 기타 전통적인 화학 합성으로 제조할 수 없는 복잡한 생물학적 제품과 같은 바이오 의약품이 포함됩니다. 바이오매뉴팩처링은 종종 세포 배양, 발효, 정제, 품질 관리 등 다양한 고급 공정을 포함하며, 고도로 제어된 환경과 첨단 생물반응기 시스템을 필요로 합니다. 이 시장은 세계 환자들이 구명과 생명 강화를 위한 치료제를 확실하게 이용할 수 있도록 하는데 있어 매우 중요한 역할을 하고 있습니다. 맞춤형 의료에 대한 수요 증가, 만성 질환의 유병률 상승, 유전 공학의 급속한 진보에 힘입어, 바이오 매뉴팩처링 부문은 크게 성장하고 있습니다.

예를 들어 WHO에 따르면 당뇨병 환자 수는 1990년 2억 명에서 2022년 8억 3,000만 명으로 증가했습니다. 이 증가는 고소득국가에 비해 저소득 및 중산층에서 현저하게 빠르고, 세계의 건강과제의 증대와 발전도상지역에서의 적을 좁힌 예방 및 관리 전략의 필요성을 돋보이게 하고 있습니다. 단일 사용 기술, 자동화, 연속 바이오프로세싱 등의 혁신은 생산 능력을 변화시키고 효율성을 높이고 비용을 절감합니다. 생물학적 제제의 파이프라인 확대와 바이오시밀러의 출현은 시장에 새로운 기회를 창출하고 있습니다. 규제 당국도 신속한 승인과 제조 유연성을 지원하기 위해 적응하고 있습니다. 과학연구가 계속 진행되고 있는 가운데, 바이오매뉴팩처링 시장은 차세대 치료제의 신속한 개발을 가능하게 하고, 세계의 헬스케어의 과제를 다루는데 있어서 점점 필수적인 존재가 될 자세입니다.

시장 성장 촉진요인

첨단기술과 신기축 채용

주요 시장 과제

거액의 자본 지출

주요 시장 동향

연속 바이오 매뉴팩처링의 출현

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 워크플로우별(업스트림 연속, 업스트림 일회용, 다운스트림)
  • 용도별(단일클론항체, 호르몬, 백신, 재조합 단백질, 기타)
  • 최종사용자별(바이오의약품기업, 연구기관, CMO/CDMO)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 바이오매뉴팩처링 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• BGI Genomics Co. Ltd.
• PerkinElmer Inc.
• QIAGEN NV
• Eurofins Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.

제15장 전략적 제안

제16장 기업 소개와 면책사항

영문목차

Global Bio-Manufacturing Market has valued at USD 19.08 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.72% through 2030. The biomanufacturing market is a vital segment within the biotechnology and pharmaceutical industry, focusing on the large-scale production of biologically derived products. These include biopharmaceuticals such as monoclonal antibodies, therapeutic proteins, cell and gene therapies, vaccines, and other complex biological products that cannot be produced through traditional chemical synthesis. Biomanufacturing involves a range of sophisticated processes, including cell culture, fermentation, purification, and quality control, often requiring highly controlled environments and advanced bioreactor systems. This market plays a crucial role in ensuring the availability of life-saving and life-enhancing therapies for patients across the globe. Driven by increasing demand for personalized medicine, rising prevalence of chronic diseases, and rapid advances in genetic engineering, the biomanufacturing sector is experiencing substantial growth.

For instance, according to WHO, the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022. The rise has been significantly faster in low- and middle-income countries compared to high-income nations, highlighting a growing global health challenge and the need for targeted prevention and management strategies in developing regions. Innovations such as single-use technologies, automation, and continuous bioprocessing are transforming production capabilities, enhancing efficiency, and reducing costs. The expanding pipeline of biologic drugs and the emergence of biosimilars are creating new opportunities within the market. Regulatory agencies are also adapting to support accelerated approvals and manufacturing flexibility. As scientific research continues to advance, the biomanufacturing market is poised to become increasingly essential in addressing global healthcare challenges, enabling faster development and distribution of next-generation therapies.

Key Market Drivers

Adoption of Advanced Technology and New Innovation

The rise in the geriatric population and the prevalence of chronic respiratory disorders are anticipated to drive the demand for ventilators. Increasing awareness of lung cancer symptoms and a growing number of patients in medical facilities contribute to the significant market growth of ventilators. For instance, in November 2023, the FDA approved Ixchiq, the first vaccine for chikungunya, for adults aged 18 and older. In December 2023, the FDA approved Casgevy and Lyfgenia-the first cell-based gene therapies-for treating sickle cell disease in patients aged 12 and older, marking major milestones in infectious disease prevention and genetic disorder treatment. However, it should be noted that the use of mechanical ventilation may pose certain risks, such as increased infection risk and potential damage to the lungs. These considerations should be taken into account when assessing the market growth potential of Bio-Manufacturing. Advanced technologies such as automation, robotics, and process control systems can streamline biomanufacturing processes, reduce human error, and enhance overall production efficiency. This can lead to quicker turnaround times and increased production capacity, meeting the growing demand for biologics. Innovative bioreactor designs, single-use technologies, and flexible manufacturing platforms allow for easier scalability of production. As demand for bio manufactured products grows, the ability to quickly scale up production will become essential. Continuous manufacturing approaches, as opposed to traditional batch processes, can lead to consistent product quality, reduced wastage, and improved resource utilization. These advantages can boost demand for bio manufactured products.

Key Market Challenges

Huge Capital Expenditure

The biomanufacturing process involves intricate and specialized equipment, facilities, and technologies, which can require significant financial investments. Setting up a biomanufacturing facility or upgrading existing infrastructure requires substantial initial capital investment. This includes the construction or renovation of specialized cleanrooms, purchase of bioreactors, purification equipment, and other sophisticated tools necessary for biopharmaceutical production. The substantial capital required for biomanufacturing can divert resources away from other critical areas such as research and development, marketing, and business expansion. This resource allocation challenge can impact a company's overall growth strategy. The high capital expenditure can result in overestimation or underutilization of manufacturing capacity. If demand for the manufactured product is lower than anticipated, the investment may not yield the expected returns.

Key Market Trends

Emergence of Continuous Biomanufacturing

The emergence of continuous biomanufacturing has the potential to significantly boost the growth of the biomanufacturing industry in the future. Continuous biomanufacturing represents a departure from traditional batch processes by enabling the seamless, uninterrupted production of biopharmaceuticals and other biologically derived products. This innovative approach offers several benefits that can positively impact efficiency, flexibility, cost-effectiveness, and overall market expansion. Continuous biomanufacturing allows for continuous monitoring and adjustment of process parameters in real-time. This leads to improved process control, reduced variability, and enhanced product consistency, resulting in higher process efficiency and reduced production times. Continuous biomanufacturing systems are generally more compact and require less physical space than traditional batch systems. This reduction in facility footprint can lead to cost savings and greater flexibility in facility design and location. Continuous biomanufacturing can enable higher production capacities by running processes continuously, thereby increasing output without the need for significant facility expansion. This increased capacity can meet the growing demand for biopharmaceuticals and other biologically derived products.

Key Market Players

Illumina Inc.

Thermo Fischer Scientific Inc.

Oxford Nanopore Technologies plc

Agilent Technologies, Inc.

BGI Genomics Co. Ltd.

PerkinElmer Inc.

QIAGEN NV

Eurofins Scientific Inc.

F. Hoffmann-La Roche Ltd

Takara Bio Inc.

Report Scope:

In this report, the Global Bio-Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bio-Manufacturing Market, By Workflow:

• Continuous Upstream Biomanufacturing
• Single-Use Upstream Biomanufacturing
• Downstream Biomanufacturing

Bio-Manufacturing Market, By Application:

• Monoclonal Antibodies
• Hormones
• Vaccines
• Recombinant Proteins
• Others

Bio-Manufacturing Market, By End User:

• Biopharmaceutical Companies
• Research Institutions
• CMOs/CDMOs

Bio-Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bio-Manufacturing Market.

Available Customizations:

Global Bio-Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bio-Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing)
  • 5.2.2. By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others)
  • 5.2.3. By End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Bio-Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bio-Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Bio-Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Bio-Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe Bio-Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bio-Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. United Kingdom Bio-Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. Italy Bio-Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. France Bio-Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Bio-Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Bio-Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bio-Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Bio-Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Bio-Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Bio-Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Bio-Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. South America Bio-Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bio-Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Bio-Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Bio-Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Bio-Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bio-Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Bio-Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Bio-Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Illumina Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Thermo Fischer Scientific Inc.
• 14.3. Oxford Nanopore Technologies plc
• 14.4. Agilent Technologies, Inc.
• 14.5. BGI Genomics Co. Ltd.
• 14.6. PerkinElmer Inc.
• 14.7. QIAGEN NV
• 14.8. Eurofins Scientific Inc.
• 14.9. F. Hoffmann-La Roche Ltd
• 14.10. Takara Bio Inc.

15. Strategic Recommendations

16. About Us & Disclaimer